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1. Introduction 
Cardiac contraction is controlled by the cytosolic 
Ca’+ cont. Relaxation is induced by calcium removal 
from the regulatory site of troponin C, the calcium- 
binding protein that relieves the inhibition to actin- 
myosin interaction brought about by troponin I. The 
rate of relaxation is therefore dependent upon the 
calcium uptake by cardiac sarcoplasmic reticulum. 
Epinephrine is known to accelerate the rate of relax- 
ation. This effect was shown in vitro to be paralleled 
by a CAMP-dependent phosphorylation of phos- 
pholamban, accompanied by an increase in the rate of 
Ca2+ uptake and in Ca2’-Mg2+-ATPase activity of the 
cardiac sarcoplasmic reticulum calcium pump [l-9]. 
Phospholamban was shown to be phosphorylated 
in vitro at two different sites by (i) the catalytic sub- 
unit of CAMP-dependent protein kinase and (ii) a 
calcium-calmodulin dependent, membrane-bound, 
protein kinase [9]. 
It was therefore important to assess the occurrence 
of the phospholamban phosphorylation in vivo, i.e., 
in perfused hearts, and to evaluate the extent of the 
P-adrenergic control of these covalent modifications 
under conditions of stimulation or blocking of the 
P-receptors. Conversely, phospholamban phosphoryla- 
tion was also measured after perfusion in the presence 
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and absence of fluphenazine, which inhibits the inter- 
action of calmodulin with most of its target enzymes. 
2. Experimental 
PMSF was from Sigma; carrier free [32P]orthophos- 
phoric acid was purchased from NEN. Polyacrylamide 
gel electrophoresis reagents were from Bio Rad. All 
other chemicals were from Merck or analytical grade. 
Fluphenazine dihydrochloride was kindly provided 
by Squibb. 
2.1. Heart perfusion 
Perfusion experiments were performed on rat 
hearts essentially as in [lO,l I]. Wistar rats (300- 
350 g) were heparinized and after 1 h anesthetized by 
intraperitoneal injection of 4.5 ml 10% urethane. 
After 5 min the heart was removed and washed in 
cold saline. The aorta was then canulated and tied. 
The heart was perfused under a constant hydrostatic 
pressure (80 cm H20) by the Langendorff technique 
with a bicarbonate medium (PH 7.3) containing 
128.8 mM Cl-, 25 mM C03H-, 0.24 mM PO:-, 
1.2 mM SO:-, 143 mM Na+, 5.82 mM K’, 2.54 mM 
Cap, 1.19 mM Mg2+ and 11 mM glucose. The PO:- 
concentration used was low in order to increase the 
specific radioactivity in the medium during perfusion 
with 32P which was started 10 min after perfusion 
with the non-radioactive medium. After 30 min per- 
fusion with medium containing 32Pi (100 &i/ml) the 
heart was perfused with the non-radioactive solution 
for 3 min and then for 60 s with the same solution 
containing 4 PM isoproterenol or 20 PM propranolol. 
The heart was immediately homogenized for 5 s at 
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Fig.1. SDS (O.l%)-polyacrylamide (520% gradient) gel 
electrophoresis of i~proterenol-treated heart muscle homog- 
enate (273 fig protein): (A) Autoradiogram; (B) Coomassie 
blue-stained gel. 
full speed in an Omni-SorvaIl mixer, equipped with a 
microhomogenizer accessory, in 8 vol. 70 mM NaF, 
5 mM EDTA, 1 mM DTT, and 50 mM phosphate 
buffer (pH 7.0) [ 12] containing 0.3 M sucrose. In 
some experiments, 50 nM fluphenazine was added to 
the perfusion medium containing 32Pi. This 30 min 
perfusion time was chosen to allow at least partial 
entry of the drug within the cell, which recovered 
within 5-7 min after removal of fluphenazine, as 
monitored by electrocardiography. 
Sarcoplasmic reticulum was purified essentially as 
in [9]. The homogenate was centrifuged at 15 000 X 
g for 20 mm, and the supernatant was centrifuged at 
100 000 X g for 90 mm. The 100 000 X g pellet was 
resuspended and incubated overnight in a minimal 
volume of 0.1 mM PMSF, 1 mM DTT, 0.3 M sucrose 
and 10 mM Hepes buffer (PI-Ii 7.5) contain~g 0.6 M 
KCI. The suspension was then centrifuged at 100 000 
X g for 90 min and the final pellet resuspended and 
dissolved in the electrophoresis ample buffer con- 
taining 1% SDS. An aliquot of the muscle homog- 
enate was also incubated with the same buffer for 
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subsequent electrophoretic comparison. The samples 
were submitted to SDS-(0.1%) polyacrylamide 
(5-20% gradient) slab gel electrophoresis according 
to [ 131. Molecular weight markers were phosphoryfase 
b, bovine serum albumin, ovalbumin, carbonic 
anhydrase, /3-lactoglobulin, and lysozyme, of mol. wt 
97 400,68 000,43 000,29 000,17 500 and 14 300, 
respectively. The proteins were f=ed and stained with 
Coomassie blue R 250. The gel was dried under vac- 
uum and the radioactive bands detected by autoradiog 
raphy after 24 h exposure of a Kodak X-Omat R 
film. The autoradiograms and the stained gels were 
scanned with a microdensitometer MK III CS from 
Joyce-Loebl. lndividual protein bands were cut from 
the gel, dissolved in 30% hydrogen peroxide at 70°C 
and counted in 10 ml dioxane-naphthalene scintil- 
lam. 
3. Results and discussion 
When homogenates from i~proterenol-stimulated 
hearts were submitted to SDS-PAGE, [32P]phos- 
phate appeared to be incorporated into 9 major poly 
peptide chains, as shown in fig.1. Their mol. wt was 
calculated to be 98 000,48 000,40 OOO,30 000, 
26 000,23 000,19 000,lS 000 and 11 500 for 
bands a-i, respectively. Bands a, d, f, g and i can 
tentatively be assigned to phosphorylase [ 141, 
troponin I 1151, phospholamban dimer [9], myosin 
regulatory light chain [16,17] and phospholamban 
monomer [9,18], respectively. Cardiac troponin I 
does migrate upon SDS-PAGE with app. mol. wt 
29 500 [17], which is si~i~c~tly higher than the 
23 550 mol. wt computed from the amino acid 
sequence [19]. 
After purification of SRvesicles from isoproterenol- 
treated hearts, the autoradiogr~ illustrated in fig2A, 
upper trace, shows mainly the 40 000,30 000, 
23 000, 19 000 and 11 500 mol. wt [32P]polypeptide 
chains. The Coomassie blue-stained electrophoreto- 
gram of SR vesicles obtained from either isoproterenol 
or propranolol-treated hearts (fig.2B) shows a slight 
contamination by contractile proteins, namely myosin 
heavy and light chains, actin and troponin. This 
explains the observed [32P]phosphate incorporation 
into the 30 000 and 19 000 mol. wt bands which are 
troponin I and myosin regulatory light chain, res- 
pectively. Such a contam~lation was expected from 
the adopted purification procedure since it included 
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Fig.2. SDS (O.l%)-polyacrylamide (5-20% gradient) gel 
electrophoresis of rat heart sarcoplasmic reticulum (300 fig 
protein): (A) Autoradiogram of sarcoplasmic reticulum 
obtained from isoproterenol~timu~ted heart (upper curve) 
and propranolol-treaty heart (lower curve). Radioactivity 
under the 22 000 and 11000 mol. wt peaks (upper curve) 
was 960 and 1040 cpm, respectively. (B) Coomassie blue- 
stained gel described in (A) (the same curve is obtained for 
both pagonist and pantagonist-treated hearts). 
only a single high salt wash because of the scarcity of 
the starting material. 
Major differences were observed when autoradio- 
grams from isoproterenol-treated (fig.2A, upper trace) 
and propranolol-treated hearts (fig2A, lower trace) 
were compared. The phospho~lation of a 48 000 
mol. wt chain and of the 19 000 mol. wt regulatory 
light chain was unaffected by stimulation or blocking 
of the fl receptors. In contrast, the phosphorylation 
of the 40 000 mol. wt protein and of troponin I (mol. 
wt 30 000) was essentially suppressed by propranolol, 
and appeared therefore to be catalyzed only by CAMP- 
dependent protein kinases, as already amply docu- 
mented for troponin I [11,15,17]. The phosphoryla- 
tion of phospholamban dimer and monomer was 
reduced after propranolol treatment to -49% of the 
level in isoproterenoI-stimulated h arts. Since troponin 
I phospho~lation was abolished after exposure to 
propranolol, the following two major conclusions can 
be drawn: 
Phospholamban can be phospho~lated invivo by 
a protein kinase that is different from CAMP- 
dependent protein kinase, presumably by the cal- 
cium+almodulindependent protein kinase in [9]; 
Additional phosphorylation of phospholamban is 
brought about by CAMP-dependent protein kinase 
after stimulation by isoproterenol. 
These conclusions are supported by the results of 
experiments in which fluphenazine was added to the 
32Pi-containing p erfusion medium. In the absence of 
either P-agonist or antagonist, he phosphorylation of
phospholamban dimer + monomer was reduced by 
the ~uphenaz~e treatment to -37% of control. 
When the hearts were stimulated by isoproterenol, 
fluphenazine reduced phospholamban phosphoryla- 
tion to -32% of control. Comparison of propranol- 
treated hearts with or without previous fluphenazine 
treatment was not performed because of cardiac arrest 
induced by the P-blocker on fluphen~ine treated 
hearts. 
Therefore, phospholamban phosphorylation 
appears to be inhibited independently either by fl- 
antagonists orby fluphenazine, which is known to 
bind to c~odul~ in the presence of Cap and there- 
by to prevent its interaction with calmodu~-stimul- 
ated enzymes [203, assuming that the intracellular 
concentration of the drug was high enough. This 
independent effect of propranolol and fluphenazine 
seems to rule out the possibility that phospholamban 
is phospho~lated only by CAMP-dependent protein 
kinase, or that it is more slowly dephospho~lated 
than troponin I by phosphoprotein phosphatase. 
These data are fully consistent with the observa- 
tions made on purified canine cardiac SR vesicles 
phosphorylated in vitro by either CAMP or Cap’- 
dependent protein kinases 191. They also indicate 
that phospholamban does not seem to be in the 
dephospho form in vivo even under conditions where 
the CAMP concentration isat its basal level. It can be 
assumed that SR vesicle preparations are dephos- 
phorylated in vitro by phosphoprote~ phosphatase 
and cannot be rephosphorylated at the Ca*-dependent 
site in the absence of exogenous calmodulin, under 
the experimental conditions used to measure the rate 
of Ca” uptake. Therefore, figures previously reported 
for the maximal calcium uptake activity of cardiac 
SR vesicles may be si~i~c~tly lower than the rate 
obtained in viva, where the Cap-dependent phos- 
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phorylation appears to occur independently of the 
CAMP-dependent one. This raises the interesting 
possibility that the cardiac SR has the capability of 
moving in and out of the cytosol the whole of the 
Ca*’ that are transported during systole and diastole, 
without the postulated help of the mitochondrial 
calcium pump [21]. 
Acknowledgements 
This work was supported in part by grants from 
CNRS (ATP Modulation de l’action des hormones au 
niveau cellulaire), from INSERM (CRL 78.4.086.1 
and 79.4.151.3 and ATP 63.7895 Biologie et phar- 
macologie de la fibre musculaire cardiaque), from 
DGRST (ACC Biologie et fonction du myocarde), 
from FacultC de Medecine, NATO (grant no. 1688) 
and Fondation pour la Recherche Medicale Francaise. 
References 
[l] Wray, H. L., Gray, R. R. and Olsson, R. A. (1973) 
J. Biol. Chem. 248,1496-1498. 
[2] Kirchberger, M. A., Tada, M. and Katz, A.M. (1974) 
J. Biol. Chem. 249,6166-6173. 
[3] Tada, M., Kirchberger, M. A. and Katz, A. M. (1975) 
J. Biol. Chem. 250,2640-2647. 
[4] Kirchberger, M. A. and Tada, M. (1976) J. Biol. Chem. 
251,725-729. 
[5] Schwartz, A., Entman, M. L., Kaniike, K., Lane, L. K., 
Van Winkle, W. B. and Bornet, E. P. (1976) Biochim. 
Biophys. Acta 426,57-72. 
[6] Will, H., Blanck, J., Smettan, G. and Wollenberger, A. 
171 
181 
191 
1101 
[ill 
[I21 
1131 
1141 
[I51 
1161 
f171 
1181 
1191 
WI 
1211 
(1976) Biochim. Biophys. Acta 449,295-303: 
Wray, H. L. and Gray, R. R. (1977) Biochim. Biophys. 
Acta 461,441-459. 
Tada, M., Ohmori, F., Yamada, M. and Abe, H. (1979) 
254,319-326. 
Le Peuch, C. J., Haiech, H. and Demaille, J. G. (1979) 
Biochemistry 18,5150-5157. 
Krebs, H. A. and Henseleit, K. (1932) Hoppe-Seyler’s 
Z. Physiol. Chem. 210,33-66. 
England, P. J. (1975) FEBS Lett. 50,57-60. 
Holroyde, M. J., Small, D. A. P., Howe, E. and Solaro, 
R. J. (1979) Biochim. Biophys. Acta 587,628-637. 
Laemmli, U.K. (1970) Nature 227,680-685. 
McCullough, T. E. and Walsh, D. A. (1979) J. Biol. 
Chem. 254,7345-7352. 
England, P. J. (1976) Biochem. J. 160,295-304. 
Solaro, R. J., Moir, A. J. G. and Perry, S. V. (1976) 
Nature 262,615-617. 
Kopp, S. J. and Barany, M. (1979) J. Biol. Chem. 254, 
12007-12012. 
LePeuch,C.J.,LePeuch,D.A.M.andDemaille,J.G. 
(1980) Biochemistry in press. 
Grand, R. J. A., Wilkinson, J. M. and Mole, L. E. (1976) 
Biochem. J. 159,633-641. 
Levin, R. M. and Weiss, B. (1977) Mol. Pharmacol. 13, 
690-697. 
Carafoli, E. and Crompton, M. (1978) Curr. Top. 
Membr. Trans. 10, 151-216. 
168 
